MFX

Regulatory T cell (Treg) therapy is a ground breaking approach to cellular immunotherapy. They have the potential to combat autoimmune diseases, fight transplant rejection and treat inflammatory conditions. However, they bring a higher level of complexity when compared to other adoptive cell therapies, like CAR-Ts. Find out more about Tregs, the challenges of their isolation, and the potential we’ve discovered in our own studies 👇 #tregcells #cgt #MFX #celltherapy

Didn’t make it to Advanced Therapies last week? Once again, the team at Terrapinn hosted a great event in London! We’ve loved the opportunity to catch up with old friends and new connections and hear the latest advancements in the industry. Take a look at some of our take homes (and our new additions to the team 👀) 🧬Panellists from across CGTs identified the most prominent challenges facing the industry including adapting ways of working to integrate with healthcare systems, being able to collect, process, and analyse large amounts of data effectively, considering how practical therapies are for end users (HCPs and patients), and optimising the entire value chain to improve efficiency 🧬When talking about patient access, it doesn’t just mean affordability for healthcare systems. Having a good understanding of the patient community for a therapy is important for fundraising, therapy development, and patient uptake. Including patient advocacy groups early on (including in conferences like this) will help improve patient access down the line 🧬Autologous therapies currently have a slight advantage in fundraising as they have strong data and more approvals behind them. However, it is a very narrow lead. In vivo technologies such as gene therapies are predicted to advance, and eventually overtake autologous therapies due to the high levels of innovation in the space over the past decade 🧬Tech innovation is rapid at the moment, with a lifespan of 5-10 years for a piece of equipment. To mitigate the inevitable outdating of tech, companies can start validating new equipment whilst the legacy kit is still running and invest in modular systems that are easier to modify or switch out. Single use kits are also an option, but less economical and sustainable #AT25 #cgt #events #cytoengine #mfx

We had a blast at Advanced Therapies this week!   🎉 Not only did we get to hear about the latest updates in the #cellandgenetherapy sector and catch up with some of our amazing collaborators we also got the added bonus of hanging out with not 1️⃣ but 2️⃣ new team mates! 🎉 Welcome to the MFX team Eleni Kotsiou and Katy Newton we’re super excited to have both of you join us to help unleash the process optimisation power of the #CytoEngine And if you found this update exciting, don't forget to sign up for our newsletter - The MF-X-Files 👽 where you'll be first to hear our latest news! Link in the comments! ⬇️ ⬇️

Advanced Therapies Day1! Welcome to the team Katy! Katy’s speaking on a panel this afternoon at 5.30pm on “staying agile and embracing technological innovations in cell therapy manufacturing” If you don’t manage to catch that then don’t worry as Antoine will be talking tomorrow at 12.20 on “harnessing automation, analytics and scalability to drive cell therapy innovation” #cellandgenetherapy #innovation

🎉 📢 EXCITING ANNOUNCEMENT📢 🎉 We are delighted to welcome Dr Katy Newton to the leadership team at MFX as our new Chief Scientific Officer. 🧬 Katy’s extensive experience in immunology and process development of T cell based cell therapies is coming at a critical time in the #CytoEngine's development - our automated prototypes are allowing us for the first time to run high throughput rapid process optimisation in our small volume bioreactors. 📈 Welcome to the team Katy - we look forward to seeing you and our scientists unlock the full power of automated, monitored and precision controlled bioreactors to discover better (cell driven) processes for cell based therapies. 💡 Here’s to our shared future dream of adaptive manufacturing - understanding the biology early in process optimisation to be able to give the cells what they need, when they need it. 🌟 You can catch up with Katy at the Advanced Therapies congress this week - she'll be chairing a session in the Innovation Track later today so do pop by and say hi to find out why she's excited about the #CytoEngine's potential! #cellandgenetherapy #innovation #CSO

Are you interested in the state of the art of bioprocessing automation and analytics at the R&D and manufacturing scales for cell therapies? See you next week :) Date: Wednesday 19th March 2025 Time: 12:20 - 12:40 Location: ExCel, London Theatre Location: Gene Modified Cell Therapy MFX Advanced Therapies

Last week we were excited to welcome the #EcoCAR Consortium to our labs at Stevenage Bioscience Catalyst for the groups first in person technical meeting where we set out to explore how we could integrate a novel vector that captures T cells, activates and transduces in one into the MFX #CytoEngine platform to create a "1 Pot CAR-T Process". Or Project Pot Noodle as it is affectionately called! Next week we’re looking forward to exploring what the environmental impact of shortening, streamlining and intensifying the manufacturing of this innovative process could potentially be as we get ready to prepare our consortium bid for funding to develop this approach in the Sustainable Medicines Manufacturing Grand Challenge! Read more about the Expression of Interest Consortium and Grand Challenge here: https://lnkd.in/eGXfMkPt Royal Free London NHS Foundation Trust UCL Autolus Therapeutics Cell and Gene Therapy Catapult Tozaro Innovate UK #innovation #collaboration #cellandgenetherapy

We’re heading to London next week for Advanced Therapies Europe! Lindsey will be there ready to discuss all things cyto engine on both the 18th and 19th. Want to have a chat with her? Book a meeting now on the event app 📱 Make sure there’s room in your schedule to hear our CEO Antoine delivering his talk on Wednesday “Harnessing automation, analytics and scalability to drive innovation” at 12.20pm We can’t wait to see you there! #AT25 #AdvancedTherapies #MFX #cytoengine #cgt

Last month, MFX advisor Patrick Hanley, Ph.D. joined other leaders in CGTs at The White House Cell and Gene Therapy Forum. There they discussed the challenges of funding, research, manufacturing and access to CGTs. One of the solutions identified in the discussions around development and manufacturing? Enabling scalable technology. The core of the Cyto Engine technology is our scalable bioreactor cassettes. How do we make sure the way cells behave at smaller volumes translates to bigger volumes? 🎚️ Precision fluidic control: we use our microfludic know-how to precisely control the cellular environment 🔁 Parallelisation: we copy and paste that same fluidic environment, meaning that cells growing in our large bioreactor cassettes grow the same as in our smaller ones Instant scalability for your process #ATMP #microfluidics #bioreactor #celltherapy #genetherapy #cellandgenetherapy #cytoengine #MFX

We unveiled more Cyto Engine data last year ELRIG Drug Discovery 2024 💡 We’re continuously adding to the repertoire of cells that we’ve successfully tested in our Cyto Engine. So we were thrilled when the opportunity to apply Tregs came around as Treg therapies have the potential to combat a host of autoimmune and inflammatory diseases. In collaboration with AstraZeneca we explored different feeding strategies, the effect of bi-directional agitation, and seeding density on Treg expansion in our novel scalable bioreactor. If you missed it, you can download our poster on our website (link in the comments) 👇 Want to keep up to date on the development of the Cyto Engine? Sign up to our mailing list for data highlights (link in the comments) 👇 #MFX #ELRIGDrugDiscovery #CGT #advancedtherapies #AstraZeneca